Enlaza Therapeutics Funding: $161M Raised, Series A (2024)
Enlaza Therapeutics is a Biotech company based in La Jolla, California. It has raised $161M in total funding. Latest round: Series A.
Enlaza Therapeutics funding overview
Enlaza Therapeutics is a Biotech company based in La Jolla, California. Enlaza Therapeutics has raised $161M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in April 2024. The round record for Enlaza Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include J.P. Morgan Private Capital.
Enlaza Therapeutics at a glance
Total raised
$161M
Latest round
Series A
Latest round date
April 2024
Industry
Biotech
Headquarters
La Jolla, California
Notable investors
J.P. Morgan Private Capital
Frequently asked about Enlaza Therapeutics funding
How much has Enlaza Therapeutics raised?
Enlaza Therapeutics has raised $161M in total disclosed funding across the rounds on record.
Who has invested in Enlaza Therapeutics?
J.P. Morgan Private Capital are named among the investors backing Enlaza Therapeutics.
What was the latest Enlaza Therapeutics funding round?
The most recent disclosed round is a Series A, announced in April 2024.
Where is Enlaza Therapeutics based?
Enlaza Therapeutics is based in La Jolla, California.
What sector does Enlaza Therapeutics operate in?
Enlaza Therapeutics is tracked under Biotech from La Jolla, California, with $161M in disclosed funding.
When did Enlaza Therapeutics last raise?
The last disclosed Enlaza Therapeutics round closed in April 2024 at Series A.
Enlaza Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in La Jolla below to benchmark round size and investor mix.
